Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Ga101-DHAP induction in relapsed/refractory DLBCL
2013-004014-17Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete response rate (CR) after GA101-DHAP induction. Started Jun 2014; status: completed.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2013-004014-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004014-17.